Phase 2
An investigational oral MK2 inhibitor from Aclaris Therapeutics was safe and associated with promising reductions in inflammatory markers in a 12-week, Phase II a study of patients with moderate to severe rheumatoid arthritis.
VP-102, which has the potential to be the first product approved by the FDA for the treatment of molluscum contagiosum, contains a GMP-controlled formulation of cantharidin (0.7% w/v), which is delivered via a single-use applicator that allows for precise topic dosing and targeted administration.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
Being studied for GAD, OCD, AD and spinocerebellar ataxia, Biohaven’s troriluzole has now struck out in 3 late-stage studies.
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.
On January 4, the company announced slightly murky data from its first-in-patients 12-week Phase II proof-of-concept trial of BT-11 for mild to moderate ulcerative colitis.
Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days.
The COVID-19 pandemic that has upended life across the globe has also ignited a reawakening to the value of vaccines, and Hu believes the momentum will carry forward into the new year.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
The primary endpoint was change from baseline to 76 weeks in the Integrated Alzheimer’s Disease Rating Scale (iADRS).
PRESS RELEASES